---
title: "Takara Bio voluntary retirement program draws 148 employees, costs rise to ¥ 1.71 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293298668.md"
description: "Takara Bio's voluntary retirement program attracted 148 employees, exceeding the target of 120. This will incur an extra cost of ¥1.71 billion in FY2027, booked as an extraordinary loss. While annual personnel savings are projected at ¥1.11 billion, the company is also transferring its GMP cell-processing CDMO business to Sumitomo Chemical and partners via a definitive agreement expected by October 2026, refocusing on nucleic acids and proteins."
datetime: "2026-07-21T06:42:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293298668.md)
  - [en](https://longbridge.com/en/news/293298668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293298668.md)
generator: "portal-rs"
---

# Takara Bio voluntary retirement program draws 148 employees, costs rise to ¥ 1.71 billion

-   Takara Bio drew 148 applicants for a voluntary retirement program, above a plan for about 120. \* Extra retirement costs seen at JPY 1.71 billion in FY2027, booked as an extraordinary loss; JPY 1.65 billion slated for Q1. \* Annual personnel cost savings projected at JPY 1.11 billion, with JPY 576 million expected in FY2027. \* Takara Bio signed a basic agreement with Sumitomo Chemical, Sumitomo Pharma, S-RACMO to transfer its GMP cell-processing CDMO business. \* Definitive agreement targeted around October 2026; Takara Bio to refocus CDMO on nucleic acids/plasmids, proteins/enzymes, viral vectors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takara Holdings Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [4974.JP](https://longbridge.com/en/quote/4974.JP.md)
- [4005.JP](https://longbridge.com/en/quote/4005.JP.md)
- [4506.JP](https://longbridge.com/en/quote/4506.JP.md)
- [2531.JP](https://longbridge.com/en/quote/2531.JP.md)

## Related News & Research

- [Sumitomo Chemical begins mass production of 4-inch InP epiwafers](https://longbridge.com/en/news/297549828.md)
- [A: Q3 results exceeded expectations with strong growth in pharma, CDMO, and China, driving raised FY26 guidance](https://longbridge.com/en/news/297095880.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)
- [BARRA: Net loss halved and biological risks reduced, but revenue declined amid ongoing strategic transformation](https://longbridge.com/en/news/297340993.md)
- [11:00 ETCovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.](https://longbridge.com/en/news/297804526.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**